Home » Stocks » NEOS

Neos Therapeutics, Inc. (NEOS)

Stock Price: $0.749 USD -0.053 (-6.65%)
Updated Mar 4, 2021 10:25 AM EST - Market open
Market Cap 41.99M
Revenue (ttm) 56.99M
Net Income (ttm) -21.86M
Shares Out 49.76M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $0.749
Previous Close $0.803
Change ($) -0.053
Change (%) -6.65%
Day's Open 0.790
Day's Range 0.740 - 0.799
Day's Volume 829,859
52-Week Range 0.450 - 1.500

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

– Record date for each Special Meeting of Stockholders is February 5, 2021 –

InvestorPlace - 1 month ago

Penny stocks are wildly dangerous and not meant for risk-averse investors. Still, if you want to play, here are some ideas.

Other stocks mentioned: CAN, EMHTF, NEXCF, NGD, PTOTF, RFIL, SHRMF, WWR
GlobeNewsWire - 1 month ago

DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous s...

PRNewsWire - 2 months ago

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the...

Other stocks mentioned: AYTU
PRNewsWire - 2 months ago

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEO...

InvestorPlace - 2 months ago

Neos Therapeutics (NEOS) news for Thursday concerning a merger with Aytu BioScience (AYTU) has shares of NEOS and AYTU stock on the rise. The post Neos Therapeutics News: Why NEOS Stock Is Soa...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to ...

Seeking Alpha - 3 months ago

Neos Therapeutics' (NEOS) CEO Jerry McLaughlin on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous s...

InvestorPlace - 4 months ago

Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.

Other stocks mentioned: CIDM, DVAX, NOK, RYCEY, TTNP, WTRH
GlobeNewsWire - 5 months ago

DALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervou...

Seeking Alpha - 6 months ago

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

– Company to host conference call today at 8:30 a.m. EDT – – Company to host conference call today at 8:30 a.m. EDT –

GlobeNewsWire - 7 months ago

DALLAS and FORT WORTH, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...

GlobeNewsWire - 8 months ago

DALLAS and FORT WORTH, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...

Seeking Alpha - 9 months ago

Neos Therapeutics. Inc. (NEOS) CEO Jerry McLaughlin on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

-- N-desethyloxybutynin is the active ingredient in NT0502, the company’s development candidate for the treatment of sialorrhea -- -- N-desethyloxybutynin is the active ingredient in NT0502, t...

Seeking Alpha - 11 months ago

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Neos Therapeutics Valuation Appears Low Should They Report Operating Profits In 2020

GlobeNewsWire - 1 year ago

New chemical entity and selective muscarinic receptor antagonist targeting large unmet need for a new treatment that can meaningfully improve the lives of patients with neurological conditions...

Seeking Alpha - 1 year ago

Improvements At Neos Therapeutics Aren't Reflected In The Share Price

Seeking Alpha - 1 year ago

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Cash burn dropped significantly in Q2 to only $2M.

GlobeNewsWire - 1 year ago

DALLAS and FORT WORTH, Texas, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery ...

GlobeNewsWire - 1 year ago

DALLAS and FORT WORTH, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery t...

Seeking Alpha - 1 year ago

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 50.00% and -6.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Neos Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Seeking Alpha - 1 year ago

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 31.82% and 3.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Neos Therapeutics (NEOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Neos Therapeutics (NEOS) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2018 Results - Earnings Call Transcript

About NEOS

Neos Therapeutics, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydroco... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jul 23, 2015
CEO
Gerald McLaughlin
Employees
213
Stock Exchange
NASDAQ
Ticker Symbol
NEOS
Full Company Profile

Financial Performance

In 2019, NEOS's revenue was $64.65 million, an increase of 29.33% compared to the previous year's $49.99 million. Losses were -$16.90 million, -67.29% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for NEOS stock is "Strong Buy" and the 12-month stock price forecast is 1.00.

Price Target
$1.00
Analyst Consensus: Strong Buy